Overview
- Superdrug opened online sales of the MHRA‑approved semaglutide (Wegovy) tablet on Friday, July 3, 2026, through Superdrug Online Doctor and plans a phased in‑store rollout across more than 160 pharmacies and over 85 nurse services.
- The service starts from £79 for new patients and requires patients to complete a full clinical consultation before a prescription is issued.
- MHRA guidance sets eligibility as adults with a body mass index of 30 or above or a BMI of 27–30 plus at least one weight‑related comorbidity, and treatment must be used alongside diet and physical activity.
- Prescribing follows stepwise dosing—starting at 1.5 mg daily and escalating to 4 mg, 9 mg and 25 mg with at least one month at each level—and patients on certain weekly injections can be moved to the 25 mg tablet when clinically appropriate.
- Semaglutide is a GLP‑1 receptor agonist that reduces appetite by acting on brain appetite centres, common side effects are gastrointestinal symptoms, and regulators say safety will be closely monitored as private access expands and NHS decisions on wider provision are expected to affect cost and equity.